CME online

in association with the 7th Heart in Diabetes (HiD)

Heart and Kidney – Hitting Two Birds with One Stone

This is a CME Symposium Supported by an Educational Grant from AstraZeneca
Provided By:

Administrated by::
This CME online educational activity is approved for a maximum of 1.75 AMA PRA Category 1 Credits ™.
Accreditation period: August 1, 2023 – August 1, 2024

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

Heart and Kidney – Hitting Two Birds with One Stone
Agenda

Introduction & Pre-CME Questions
Mikhail N. Kosiborod, MD

The Intersection of CKD and HF- Making the Link
Matthew R. Weir, MD

Contemporary Approach to Management of CKD
Katherine R. Tuttle, MD

Management of HF Across the LVEF Spectrum
John McMurray, MD

Panel Discussion and Q&A: Do Guidelines-Directed Medical Therapy Address the Complex Patient with both HF & CKD.
Moderator: Yehuda Handelsman, MD
Panel: SMikhail N. Kosiborod, MD • John McMurray, MD • Katherine R. Tuttle, MD • Matthew R. Weir, MD
Moderator: Yehuda Handelsman, MD

Faculty

Mikhail N. Kosiborod MD, FACC, FAHA

Professor of Medicine
Saint Luke’s Mid America Heart Institute
University of Missouri-Kansas City
School of Medicine
Chair, Heart in Diabetes
Kansas City, Missouri


Yehuda Handelsman, MD, FACC, FAHA, FACP, FNLA, FASPC, FAHA, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory board, DCMi– Diabetes
CardioRenal & Metabolism Institute
Chair & Program Director, Heart in Diabetes
Tarzana, California

Matthew R. Weir, MD

Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

John McMurray, MD, BSC (Hons,), MB ChB (Hons), FRCP, FESC, FACC, FAHA
FRSE, FMedSci, OBE

Professor of Medical Cardiology and Deputy Director
Institute of Cardiovascular and Medical Sciences
Honorary Consultant Cardiologist
Queen Elizabeth University Hospital
Glasgow, Scotland

Katherine R. Tuttle MD
FASN, FACP, FNKF

Professor of Medicine, Division of Nephrology
Co-Principal Investigator
Institute of Translational Health Sciences
Executive Director for Research, Providence Health Care
Spokane, Washington

Program Description

Chronic kidney disease (CKD) and Heart failure (HF) share common etiologies, including hypertension, Diabetes, inflammation, oxidative stress, and increased RAS activity In recent years, multiple cardiovascular outcome trials (CVOTs) have shown that adverse outcomes in patients with HF and CKD may be reduced with use of a sodium glucose cotransporter 2 (SGLT2) inhibitor. Currently the SGLT2 inhibitor dapagliflozine is indicated to manage CKD and SGLT2i are now recommended as a foundational therapy across the spectrum of left ventricular ejection fraction (LVEF). This satellite symposium will explore the changing landscape of therapies for patients with HF and/or CKD, with or without diabetes. The program will be held in conjunction with the 7th Annual HID and will address gaps in physicians’ knowledge of the interconnections between CKD and heart failure and how to comprehensively manage these conditions when they are present in the same patient.




Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Describe the epidemiology and common pathophysiologic pathways of HF and CKD
  • Discuss outcome trial evidence underlying recently approved therapies for CKD in patients with and without diabetes
  • Explain how HF with different degrees of LVEF should be diagnosed and managed based on current guidelines and outcome trial evidence
  • Develop treatment strategies for patients with complicated disease, including those with HF and CKD, both with and without diabetes

    • Target Audience

    This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF in cardiometabolic Diseases with and without Diabes.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc., is accredited by the ACCME to provide continuing medical education for physicians.

    PESI, Inc, designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s).

    For information please contact: [email protected] or 818 342 1889